Previous 10 | Next 10 |
Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that it will release financial results for the second quarter of fiscal yea...
The following slide deck was published by Catalent, Inc. in conjunction with this event. For further details see: Catalent (CTLT ) Presents At 41st Annual Healthcare Conference - Slideshow
Summary Sarepta Therapeutics, Inc. net product revenues for Q4 2022 are expected to come in about 32% higher at $235.5 million; Financial results for Q4 2022 are expected late February 2023. BLA of SRP-9001 for the treatment of patients with Duchenne Muscular Dystrophy was accepted Nove...
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America. Mr. Zayas will be responsible for all of the company’s...
Avantor® and Catalent Enter into Multi-Year Supply and Services Agreement PR Newswire RADNOR, Pa. and SOMERSET, N.J. , Jan. 9, 2023 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to custome...
Summary Investors were net sellers of Catalent equity across the back end of 2022. Much of the downside is explained by diminishing Covid-19 revenues and potential near-term challenges to earnings quality. Despite this, a deeper look at its fundamentals reveals strengths in profitab...
Catalent ( NYSE: CTLT ) has signed a commercial supply agreement with Sarepta Therapeutics ( NASDAQ: SRPT ) to make SRPT's muscle wasting gene therapy candidate. As per the deal, CTLT will make SRP-9001 for the treatment of Duchenne muscular dystrophy (DMD). "The agre...
Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, and Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the signing of a commercial supply agreement for Cat...
Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that members of its executive leadership team will participate at the 41st ...
Summary Halvorsen's 13F portfolio value decreased marginally from $21.86B to $21.66B this quarter. The number of positions increased from 82 to 88. Viking Global increased Elevance Health, Visa, and McKesson while decreasing T-Mobile US, Parker Hannifin, and Fortive. They also dropped A...
News, Short Squeeze, Breakout and More Instantly...
Expansion adds more temperature-controlled storage and dedicated space for FastChain ® demand-led supply service Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced it has completed expansio...
2024-06-30 17:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-28 07:15:04 ET Barclays analyst issues EQUAL-WEIGHT recommendation for CTLT on June 28, 2024 05:28AM ET. The previous analyst recommendation was Equal-Weight. CTLT was trading at $56.41 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...